Yingfang Feng
State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine/Department Of Lymphoma, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Single-cell and bulk transcriptomics reveal a CD8+ T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma.
Journal: Frontiers in immunology
Published: August 14, 2025
Response to letter re: "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 16, 2025
Response to Letter Entitled "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 15, 2025
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma.
Journal: Expert opinion on biological therapy
Published: December 20, 2024
PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.
Journal: Frontiers in oncology
Published: December 12, 2024
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 23, 2024
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
Journal: Cancer medicine
Published: November 15, 2022
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Journal: Cell death & disease
Published: February 12, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026